Pharmacotherapy typically begins with a statin prescribed up to the highest tolerated dose to reach the LDL-C goal set for the individual.[1] If the LDL-C goal is not achieved with the maximum tolerated dose of a statin, combination therapy with ezetimibe is recommended.[1] If the LDL-C goal is still not met, the addition of a PCSK9 inhibitor is recommended.[1]
References
- ^Frank L J Visseren, François Mach, Yvo M Smulders, David Carballo, Konstantinos C Koskinas, Maria Bäck, Athanase Benetos, Alessandro Biffi, José-Manuel Boavida, Davide Capodanno, Bernard Cosyns, Carolyn Crawford, Constantinos H Davos, Ileana Desormais, Emanuele Di Angelantonio, Oscar H Franco, Sigrun Halvorsen, F D Richard Hobbs, Monika Hollander, Ewa A Jankowska, Matthias Michal, Simona Sacco, Naveed Sattar, Lale Tokgozoglu, Serena Tonstad, Konstantinos P Tsioufis, Ineke van Dis, Isabelle C van Gelder, Christoph Wanner, Bryan Williams, ESC Scientific Document Group, ESC National Cardiac Societies2021 ESC Guidelines on cardiovascular disease prevention in clinical practiceEur Heart J.(2021 Sep 7)